Identifying Atopic Dermatitis Patients at Risk for Developing Conjunctivitis During Dupilumab Treatment
NCT04276623 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2023-11-29
Summary
Study on ophthalmological comorbidities and the underlying pathomechanisms of conjunctivitis during dupilumab treatment in atopic dermatitis (AD) patients. Patients participate in the Bioday Registry.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
UMC Utrecht
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-02-25
- Primary Completion
- 2023-12-31
- Completion
- 2023-12-31
Countries
- Netherlands
Study Locations
More Related Trials
-
Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
NCT01979016 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD)
NCT02395133 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)
NCT03428646 ·Status: ACTIVE_NOT_RECRUITING
-
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277769 ·Status: COMPLETED ·Phase: PHASE3
-
The Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis
NCT07098000 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03738397 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT01859988 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Dupilumab on Allergic Contact Dermatitis
NCT03935971 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)
NCT02210780 ·Status: COMPLETED ·Phase: PHASE2
-
Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis
NCT04823130 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT02260986 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT02277743 ·Status: COMPLETED ·Phase: PHASE3
-
Open-label Study of Dupilumab in Patients With Atopic Dermatitis
NCT01949311 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis
NCT06039241 ·Status: RECRUITING
-
Study to Assess the Safety of Dupilumab (REGN668/SAR231893) Administered Concomitantly With Topical Corticosteroids (TCS) in Patients With Moderate-to-severe Atopic Dermatitis (AD)
NCT01639040 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT04195698 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
NCT03345914 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897 ·Status: RECRUITING ·Phase: PHASE3
-
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
NCT03346434 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
NCT01548404 ·Status: COMPLETED ·Phase: PHASE2
-
Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis
NCT04718870 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis
NCT01385657 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Dupilumab to Demonstrate Efficacy in Subjects With Nummular Eczema
NCT04600362 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
NCT03569293 ·Status: COMPLETED ·Phase: PHASE3